Keyphrases
Positron Emission Tomography
100%
Urokinase-type Plasminogen Activator
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Antibody-based
100%
Cancer Imaging
100%
Deferoxamine
90%
Zirconium-89 (89Zr)
90%
Tumor
50%
Tumor Uptake
30%
Binding Specificity
20%
U87MG
20%
Flow Cytometry
10%
Histology
10%
Major Organs
10%
Monoclonal Antibody
10%
Tumor Progression
10%
Expression Level
10%
Quantitative Imaging
10%
Oncologists
10%
Labeled Antibody
10%
Detailed Mechanism
10%
Biodistribution
10%
Western Blotting
10%
Microscopic Study
10%
Binding Affinity
10%
Conjugation
10%
Positron Emission Tomography Tracers
10%
LNCaP
10%
Competitive Binding Assay
10%
High Specific Activity
10%
Tumor Contrast
10%
Muscle Ratio
10%
Cancer Treatment Planning
10%
Radiochemical Yield
10%
Quantitative Positron Emission Tomography
10%
Medicine and Dentistry
Urokinase
100%
Malignant Neoplasm
100%
Positron Emission Tomography
100%
Neoplasm
90%
Zirconium 89
90%
Deferoxamine
90%
Receptor
10%
Tumor Progression
10%
Biodistribution
10%
Flow Cytometry
10%
Radioactive Tracer
10%
Binding Affinity
10%
Quantitative Imaging
10%
Competitive Binding Assay
10%
Cancer Treatment Planning
10%
Oncologist
10%
Pharmacological Blocking
10%
Monoclonal Antibody
10%
Western Blotting
10%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Urokinase
100%
Deferoxamine
90%
Zirconium 89
90%
Neoplasm
90%
Western Blot
10%
Flow Cytometry
10%
Pharmacological Blocking
10%
Tumor Growth
10%
Receptor
10%
Biodistribution
10%
Tracer
10%
Monoclonal Antibody
10%
Immunology and Microbiology
Positron Emission Tomography
100%
Immunology
100%
Western Blot
20%
Binding Affinity
20%
Monoclonal Antibody
20%
Binding Competition
20%
Pharmacological Blocking
20%